Panelists discusses how bronchiectasis differs from other respiratory diseases like asthma and COPD through symptoms, imaging findings, and pathophysiological mechanisms. Bronchiectasis is ...
Bronchiectasis is one of the most common highly heterogeneous chronic inflammatory airway diseases in China. It has a long course, heavy symptom burden, and is prone to recurrent acute exacerbations, ...
The dipeptidyl peptidase-1 (DPP1) inhibitor brensocatib became the first licensed therapy for bronchiectasis in the USA and Europe in 2025,1 based on the phase 3 ASPEN trial showing an approximate 20% ...
Patients with bronchiectasis recovering from severe COVID-19 face higher risks of exacerbation and mortality compared to nonsevere cases. The study utilized data from Korea's National Health Insurance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results